Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial

PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements

(2018) Yasuto Yoneshima et al.   LUNG CANCER

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

(2017) Lesley Seymour et al.   LANCET ONCOLOGY

Cancer treatment and survivorship statistics, 2016

(2016) Kimberly D. Miller et al.   CA-A CANCER JOURNAL FOR CLINICIANS

P2.43: Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894)

(2016) Gilberto De Lima Lopes et al.   Journal of Thoracic Oncology

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

(2016) Peter Goldstraw et al.   Journal of Thoracic Oncology

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

(2016) J. Liu et al.   Cancer Discovery

PD-L1 and c-MET expression and survival in patients with small cell lung cancer

(2016) Lulu Miao et al.   Oncotarget

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

(2015) M. Ilie et al.   ANNALS OF ONCOLOGY

The 2015 World Health Organization Classification of Lung Tumors

(2015) William D. Travis et al.   Journal of Thoracic Oncology

The dynamic pattern of recurrence in curatively resected non-small cell lung cancer patients: Experiences at a single institution

(2015) Yoshikane Yamauchi et al.   LUNG CANCER

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lung Cancer Incidence Trends by Gender, Race and Histology in the United States, 1973–2010

(2015) Rafael Meza et al.   PLoS One

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

(2014) K. Azuma et al.   ANNALS OF ONCOLOGY

Preoperative chemotherapy for non-small-cell lung cancer

(2014) Gerard G Hanna et al.   LANCET

Neoadjuvant chemo-immunotherapy modifies CD4+CD25+ regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients

(2014) Andreas Pircher et al.   LUNG CANCER

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

(2013) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Coexistence of EGFR mutation and ALK translocation in NSCLC: Literature review and case report of response to gefitinib

(2013) C. Santelmo et al.   LUNG CANCER

T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis

(2012) A. Facciabene et al.   CANCER RESEARCH

Novel Therapeutic Targets in Non-small Cell Lung Cancer

(2011) Filip Janku et al.   Journal of Thoracic Oncology

Non-small-cell lung cancer

(2011) Peter Goldstraw et al.   LANCET

New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non–Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy

(2010) Mizuki Nishino et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey

(2010) Daniel Morgensztern et al.   Journal of Thoracic Oncology

Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation

(2010) Jean-Yves Douillard et al.   Journal of Thoracic Oncology

Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer

(2009) Rodrigo Arriagada et al.   JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer

(2008) Wenzhao Zhong et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY